Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naïve HBI0101 CART Therapy in Relapsed/Refractory Multiple Myeloma
NCT07333430Phase 1Recruiting
- Sponsor
- Hadassah Medical Organization
- Start
- Jan 2026
- Primary completion
- Dec 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NXC-201 in multiple myeloma (MM), sponsored by Hadassah Medical Organization. Primary endpoints: Maximum Tolerated Dose at 21 days and Safety Evaluation at 24 months. Started Jan 2026; status: recruiting.
02
Drugs
NXC-201
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07333430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07333430.